Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Dokl Biol Sci ; 474(1): 106-109, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28702721

RESUMO

Parkinson's disease (PD) is the second most common severe neurodegenerative disorder that is characterized by progressive degeneration of dopaminergic neurons (DA neurons) in the substantia nigra pars compacta (SNpc) region of the brain. In the present study, we investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism. It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals. At the same time, Selank decreased level of anxiety of rats with toxic damage of DA neurons in elevated cross shaped maze. Previously such effects of Selank were revealed in healthy rodents (rats and mice) with different models of psycho-emotional stress. Therefore, toxic damage of substantia nigra does not affect the response of the rat organism on this peptide.


Assuntos
Doença de Parkinson/tratamento farmacológico , Transtornos Parkinsonianos/tratamento farmacológico , Hormônio Adrenocorticotrópico/análogos & derivados , Hormônio Adrenocorticotrópico/uso terapêutico , Animais , Ansiedade/tratamento farmacológico , Modelos Animais de Doenças , Neurônios Dopaminérgicos/efeitos dos fármacos , Neurônios Dopaminérgicos/metabolismo , Masculino , Oligopeptídeos/uso terapêutico , Oxidopamina/toxicidade , Doença de Parkinson/etiologia , Transtornos Parkinsonianos/induzido quimicamente , Parte Compacta da Substância Negra/efeitos dos fármacos , Parte Compacta da Substância Negra/metabolismo , Fragmentos de Peptídeos/uso terapêutico , Ratos
2.
Artigo em Russo | MEDLINE | ID: mdl-24450168

RESUMO

The effect of single and course administration of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) in the dose 200 microg/kg on the rat hippocampus transcriptional profile were studied using cDNA microarray technology. It was shown that mRNA levels of 36 genes changed more than 2-fold after a single intranasal Selank administration, and 20 genes--after course administration. It should be noted that most of them encode proteins associated with the plasma membrane (including transmembrane proteins). This suggests that Selank is able to regulate ion homeostasis of hippocampal cells and thereby modulate different ion-dependent processes, which include the processes of learning and memory formation.


Assuntos
Hipocampo/metabolismo , Homeostase/efeitos dos fármacos , Oligopeptídeos/administração & dosagem , Transcriptoma/genética , Animais , Linhagem Celular , Membrana Celular/efeitos dos fármacos , Hipocampo/citologia , Hipocampo/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos/métodos , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ratos , Transcriptoma/efeitos dos fármacos
3.
Genetika ; 47(5): 711-4, 2011 May.
Artigo em Russo | MEDLINE | ID: mdl-21786679

RESUMO

A study of the immunomodulating effect of selank showed that the total peptide and its fragment significantly change the expression of the genes for chemokines, cytokines, and their receptors in mouse spleen 6 and 24 h after administration of a single dose. Changes in the mRNA level of the majority of the genes under study were similarly observed after the administration of Gly-Pro, which was earlier identified as a selank pharmacophor, a minimum fragment with anitiviral activity. Pharmacological preparations based on endogenous regulatory peptides are studied intensely because they are the most promising class of drugs and have almost no side effects. The class includes selank, which is a synthetic analog of taftsin. Selank exerts anxiolytic and nootropic effects and, on the other hand, has pronounced antiviral properties.


Assuntos
Ansiolíticos/farmacologia , Antivirais/farmacologia , Quimiocinas/genética , Citocinas/genética , Expressão Gênica/efeitos dos fármacos , Fatores Imunológicos/farmacologia , Nootrópicos/farmacologia , Oligopeptídeos/farmacologia , Animais , Ansiolíticos/química , Antivirais/química , Fatores Imunológicos/química , Camundongos , Nootrópicos/química , Oligopeptídeos/química , RNA Mensageiro/genética , Receptores de Citocinas/genética , Tuftsina/química , Tuftsina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA